Filing Flows › Cytosorbents (CTSO) › Q3 2025
Cytosorbents (CTSO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Cytosorbents (CTSO) reported revenue of $9.5M for the third quarter 2025 (Q3 2025), +10% from a year earlier and -1% from the quarter before. Operating margin was -30.2%, net loss $3.2M (33.4% of revenue).
Cytosorbents, Q3 2025: revenue $9.5M (+10% year over year), operating margin -30.2%, net loss $3.2M, operating cash flow −$2.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.5M | -1% | +10% |
| Operating profit | −$2.9M | — | — |
| Net earnings | −$3.2M | -263% | — |
| Operating cash flow | −$2.6M | — | — |
What changed
Revenue was $9.5M in Q3 2025, up 10% year over year and down 1% from the previous quarter.
Gross margin was 70.3%, up 9.3 points from a year earlier. Operating costs exceeded revenue by $2.9M, an operating margin of -30.2%. Operating expenses fell 6% while revenue rose 10%. The quarter ended with a net loss of $3.2M, after a profit of $1.9M the previous quarter.
Operating cash flow was −$2.6M. Non-cash charges added back $364K of depreciation and amortization and $488K of share-based compensation. Working capital and other items used $259K. Capital expenditures of $17K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was Cytosorbents' revenue in the third quarter 2025?
Cytosorbents (CTSO) reported revenue of $9.5M for the third quarter 2025 (Q3 2025), +10% from a year earlier and -1% from the quarter before.
Was Cytosorbents profitable in the third quarter 2025?
Operating loss was $2.9M (-30.2% of revenue) and net loss $3.2M.
Source: Cytosorbents 10-Q on SEC EDGAR.